Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
Publication/Presentation Date
11-1-2011
Volume
22
Issue
6
First Page
447
Last Page
450
ISSN
1531-7021
Published In/Presented At
Huggins, A., & Sergott, R. C. (2011). Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety. Current opinion in ophthalmology, 22(6), 447–450. https://doi.org/10.1097/ICU.0b013e32834be03b
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
21946305
Department(s)
Administration and Leadership
Document Type
Article
COinS